Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea · Delayed Price · Currency is KRW 1,749,000
+39,000 (2.28%)
Last updated: Feb 19, 2026, 11:35 AM KST
Samsung Biologics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 4,557,000 | 4,547,322 | 3,694,589 | 3,001,295 | 1,568,007 |
Other Revenue | - | - | - | -0 | - |
| 4,557,000 | 4,547,322 | 3,694,589 | 3,001,295 | 1,568,007 | |
Revenue Growth (YoY) | 0.21% | 23.08% | 23.10% | 91.41% | 34.62% |
Cost of Revenue | 2,040,000 | 2,273,151 | 1,900,080 | 1,540,526 | 844,657 |
Gross Profit | 2,517,000 | 2,274,171 | 1,794,509 | 1,460,769 | 723,350 |
Selling, General & Admin | 447,000 | 758,510 | 535,421 | 380,456 | 169,630 |
Research & Development | - | 144,649 | 81,588 | 45,884 | 954.22 |
Amortization of Goodwill & Intangibles | - | 13,629 | 9,977 | 7,700 | 4,572 |
Other Operating Expenses | - | 11,145 | 10,339 | 7,448 | 1,804 |
Operating Expenses | 447,000 | 954,119 | 680,829 | 477,142 | 186,040 |
Operating Income | 2,070,000 | 1,320,052 | 1,113,680 | 983,627 | 537,309 |
Interest Expense | - | -50,057 | -81,596 | -64,064 | -14,707 |
Interest & Investment Income | - | 63,839 | 95,650 | 53,293 | 9,656 |
Earnings From Equity Investments | - | 2,660 | -499.42 | 27,260 | 13,853 |
Currency Exchange Gain (Loss) | - | 77,140 | -11,186 | -63,503 | 17,874 |
Other Non Operating Income (Expenses) | 49,000 | 19,789 | 2,652 | 2,347 | 4,494 |
EBT Excluding Unusual Items | 2,119,000 | 1,433,423 | 1,118,701 | 938,960 | 568,479 |
Gain (Loss) on Sale of Investments | - | 597.28 | 5,152 | 72,653 | 269.12 |
Gain (Loss) on Sale of Assets | - | -2,199 | -3,866 | -2,588 | -7,466 |
Asset Writedown | - | -61,770 | - | - | - |
Pretax Income | 2,119,000 | 1,370,052 | 1,119,987 | 1,009,025 | 561,283 |
Income Tax Expense | 505,000 | 286,736 | 262,296 | 210,968 | 167,693 |
Earnings From Continuing Operations | 1,614,000 | 1,083,316 | 857,691 | 798,056 | 393,589 |
Earnings From Discontinued Operations | 170,000 | - | - | - | - |
Net Income to Company | 1,784,000 | 1,083,316 | 857,691 | 798,056 | 393,589 |
Net Income | 1,784,000 | 1,083,316 | 857,691 | 798,056 | 393,589 |
Net Income to Common | 1,784,000 | 1,083,316 | 857,691 | 798,056 | 393,589 |
Net Income Growth | 64.68% | 26.31% | 7.47% | 102.76% | 63.33% |
Shares Outstanding (Basic) | 46 | 46 | 46 | 45 | 43 |
Shares Outstanding (Diluted) | 46 | 46 | 46 | 45 | 43 |
Shares Change (YoY) | - | - | 1.95% | 5.51% | - |
EPS (Basic) | 38538.85 | 23402.33 | 18528.27 | 17592.79 | 9146.19 |
EPS (Diluted) | 38538.85 | 23402.33 | 18528.27 | 17577.11 | 9146.19 |
EPS Growth | 64.68% | 26.31% | 5.41% | 92.18% | 63.33% |
Free Cash Flow | - | 355,682 | 671,158 | -3,792 | 48,343 |
Free Cash Flow Per Share | - | 7683.62 | 14498.68 | -83.52 | 1123.38 |
Gross Margin | 55.23% | 50.01% | 48.57% | 48.67% | 46.13% |
Operating Margin | 45.42% | 29.03% | 30.14% | 32.77% | 34.27% |
Profit Margin | 39.15% | 23.82% | 23.21% | 26.59% | 25.10% |
Free Cash Flow Margin | - | 7.82% | 18.17% | -0.13% | 3.08% |
EBITDA | - | 1,919,154 | 1,603,462 | 1,291,892 | 699,098 |
EBITDA Margin | - | 42.20% | 43.40% | 43.04% | 44.59% |
D&A For EBITDA | 694,023 | 599,101 | 489,782 | 308,264 | 161,789 |
EBIT | 2,070,000 | 1,320,052 | 1,113,680 | 983,627 | 537,309 |
EBIT Margin | 45.42% | 29.03% | 30.14% | 32.77% | 34.27% |
Effective Tax Rate | 23.83% | 20.93% | 23.42% | 20.91% | 29.88% |
Advertising Expenses | - | 17,042 | 11,916 | 8,829 | 5,349 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.